Exact Sciences (NASDAQ:EXAS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.
Valuation and Earnings
This table compares Exact Sciences and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Exact Sciences | $876.29 million | 24.22 | $-83,990,000.00 | ($1.49) | -84.26 |
Regeneron Pharmaceuticals | $7.86 billion | 6.47 | $2.12 billion | $21.47 | 22.13 |
Regeneron Pharmaceuticals has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Exact Sciences and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Exact Sciences | -25.27% | -11.71% | -6.74% |
Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
Insider and Institutional Ownership
90.4% of Exact Sciences shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.8% of Exact Sciences shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Exact Sciences has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for Exact Sciences and Regeneron Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Exact Sciences | 0 | 3 | 11 | 0 | 2.79 |
Regeneron Pharmaceuticals | 0 | 5 | 14 | 1 | 2.80 |
Exact Sciences currently has a consensus target price of $150.3333, suggesting a potential upside of 19.75%. Regeneron Pharmaceuticals has a consensus target price of $637.2083, suggesting a potential upside of 34.10%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Exact Sciences.
Summary
Regeneron Pharmaceuticals beats Exact Sciences on 12 of the 15 factors compared between the two stocks.